LXRX vs. CLDX, MNKD, BCRX, NVAX, INVA, OPK, DVAX, ZBIO, GERN, and MYGN
Should you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), MannKind (MNKD), BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Innoviva (INVA), OPKO Health (OPK), Dynavax Technologies (DVAX), Zenas BioPharma (ZBIO), Geron (GERN), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry.
Lexicon Pharmaceuticals vs. Its Competitors
Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.
74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 4.4% of Celldex Therapeutics shares are owned by company insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Celldex Therapeutics currently has a consensus price target of $46.13, indicating a potential upside of 75.92%. Lexicon Pharmaceuticals has a consensus price target of $3.23, indicating a potential upside of 112.17%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.
In the previous week, Celldex Therapeutics had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 2 mentions for Celldex Therapeutics and 1 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.13 beat Celldex Therapeutics' score of 0.53 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.
Lexicon Pharmaceuticals has a net margin of -206.43% compared to Celldex Therapeutics' net margin of -3,446.88%. Celldex Therapeutics' return on equity of -27.61% beat Lexicon Pharmaceuticals' return on equity.
Celldex Therapeutics has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500.
Celldex Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Celldex Therapeutics and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Lexicon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexicon Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:LXRX) was last updated on 10/8/2025 by MarketBeat.com Staff
